

09-01-06

1FW

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/554,252
Filing Date	October 24, 2005
First Named Inventor	William C. Sessa et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	7
Attorney Docket Number	YU/110

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <i>All</i> Cited References with PTO/SB/08A and PTO/SB/08B
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
The Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 003802-0013. A duplicate copy of this letter is transmitted herewith.		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fish & Neave IP Group Ropes and Gray LLP		
Signature			
Printed name	Jane T. Gunnison		
Date	August 30, 2006	Reg. No.	38,479

## CERTIFICATE OF EXPRESS MAILING – Express Mail No. EV669638814US

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" under 37 C.F.R. 1.10 on the date indicated above and is addressed to: the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Typed or printed name

Isatta Smith

Date 8/30/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
www.USCourtForms.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William C. Sessa et al.  
Application No. : 10/554,252  
Confirmation No. : Not Yet Assigned  
Filed : October 24, 2005  
For : A NOVEL REGULATOR OF ENDOTHELIAL CELL  
FUNCTION AND VESSEL REMODELING  
Group Art Unit : Not Yet Assigned  
Examiner : Not Yet Assigned

New York, New York  
August 30, 2006

**Mail Stop: Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make the following references of record in the above-identified patent application (copies of said references are enclosed):<sup>1</sup>

---

<sup>1</sup> Applicants submit herewith Forms PTO/SB-08A and 08B, with the references listed therein.

U.S. PATENT DOCUMENTS

<u>Applicant</u>	<u>Patent No.</u>	<u>Issue Date</u>
Adair et al.	5,877,293	March 2, 1999
Nakatani et al.	5,886,152	March 23, 1999
Carter et al.	6,054,297	April 25, 2000

FOREIGN PATENT DOCUMENTS

<u>Publication No.</u>	<u>Publication Date</u>
WO 00/60083	October 12, 2000

OTHER DOCUMENTS

Acevedo et al., "A New Role For Nogo As A Regulator Of Vascular Remodeling" Nature Medicine, 10(4):382-388 (2004)

Anderson, "The Caveolae Membrane System" Annu. Rev. Biochem., 67:199-225 (1998)

Goldberg et al., "Nogo In Nerve Regeneration" Nature, 403(6768):369-370 (2000);

Li Qin et al., "Link Of A New Type of Apoptosis-Inducing Gene ASY/NOG-B To Human" Oncogene, 20(30):3929-3936 (2001)

Oertle et al., "Do Cancer Cells Die Because Of Nogo-B?" Oncogene, 22(9):1390-1399 (2003)

Oertle et al., " Genomic Structure And Functional Characterisation Of The Promoters Of Human And Mouse Nogo/rtn4" J. Mol. Biol., 325 (2):299-323 (2003)

Prinjha et al., "Inhibitor Of Neurite Outgrowth In Humans" Nature, 403(6768):383-384 (2000)

Ross, "The Pathogenesis of Atherosclerosis: A Perspective For The 1990s" Nature, 362:801-809 (1993)

Shaul and Anderson, "Role of Plasmalemmal Caveolae In Signal Transduction" Am. J. Physiol., 275(5):L843-851 (1998)

Ward et al., "Arterial Remodeling Mechanisms And Clinical Implications" Circulation, 102:1186-1191 (2000)


Watari and Yutsudo, "Multi-Functional Gene ASY/Nogo/RTN-X/RTN4: Apoptosis, Tumor Suppression, And Inhibition Of Neuronal Regeneration" Apoptosis, 8:5-9 (2003).


It is respectfully requested that (1) the above-cited documents be fully considered by the Examiner during the examination of this application; (2) the Examiner initial the enclosed copy of Forms PTO/SB-08A and 08B in the appropriate places to indicate that the references have been considered and return a copy of the initialed Form to the undersigned and (3) the above-cited documents be printed on any patent issuing from this application.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director of the United States Patent and Trademark Office is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075 (Order No. 003802-0013). A duplicate copy of this Statement is transmitted herewith.

An early and favorable action is respectfully requested.

Respectfully submitted,

  
Jane T. Gunnison (Reg. No. 38,479)  
Attorney for Applicants  
Fish & Neave IP Group  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary.)*

Shee

1

2

**Complete if Known**

Application Number	10/554,252
Filing Date	October 24, 2005
First Named Inventor	William C. Sessa et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	YU/110

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)				
		WO 00/60083	10/12/00			


Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
[www.USCourtForms.com](http://www.USCourtForms.com)



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2**of **2**

<b>Complete if Known</b>	
Application Number	10/554,252
Filing Date	October 24, 2005
First Named Inventor	William C. Sessa et al.
Art Unit	Not Yet Assigned
Examiner Name	Not yet Assigned

Attorney Docket Number **YU/110****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Acevedo et al., "A New Role For Nogo As A Regulator Of Vascular Remodeling" Nature Medicine, 10(4):382-388 (2004)	
		Anderson, "The Caveolae Membrane System" Annu. Rev. Biochem., 67:199-225 (1998)	
		Goldberg et al., "Nogo In Nerve Regeneration" Nature, 403(6768):369-370 (2000);	
		Li Qin et al., "Link Of A New Type of Apoptosis-Inducing Gene ASY/NOG-B To Human" Oncogene, 20(30):3929-3936 (2001)	
		Oertle et al., "Do Cancer Cells Die Because Of Nogo-B?" Oncogene, 22(9):1390-1399 (2003)	
		Oertle et al., " Genomic Structure And Functional Characterisation Of The Promoters Of Human And Mouse Nogo/rtn4" J. Mol. Biol., 325 (2):299-323 (2003)	
		Prinjha et al., "Inhibitor Of Neurite Outgrowth In Humans" Nature, 403(6768):383-384 (2000)	
		Ross, "The Pathogenesis of Atherosclerosis: A Perspective For The 1990s" Nature, 362:801-809 (1993);	
		Shaul and Anderson, "Role of Plasmalemmal Caveolae In Signal Transduction" Am. J. Physiol., 275(5):L843-851 (1998)	
		Ward et al., "Arterial Remodeling Mechanisms And Clinical Implications" Circulation, 102:1186-1191 (2000)	
		Watari and Yutsudo, "Multi-Functional Gene ASY/Nogo/RTN-X/RTN4: Apoptosis, Tumor Suppression, And Inhibition Of Neuronal Regeneration" Apoptosis, 8:5-9 (2003).	

Examiner Signature	Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.